Literature DB >> 2684463

Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures.

H Mirels1.   

Abstract

A weighted scoring system is proposed to quantify the risk of sustaining a pathologic fracture through a metastatic lesion in a long bone. This system objectively analyzes and combines four roentgenographic and clinical risk factors into a single score. Retrospective analysis of metastatic long bone lesions was completed in 78 lesions that had been irradiated without prophylactic surgical fixation. Clinical data and roentgenograms were scored prior to irradiation by independent observers. The outcome identified 51 lesions that did not fracture during the subsequent six months and 27 lesions that fractured within six months. A mean score of 7 was found in the nonfracture group, whereas the fracture group had a mean score of 10. The percentage risk of a lesion sustaining a pathologic fracture could be predicted for any given score. As the score increased above 7, so did the percentage risk of fracture. It is suggested that all metastatic lesions in long bones be evaluated prior to irradiation. Lesions with scores of 7 or lower can be safely irradiated without risk of fracture, while lesions with scores of 8 or higher require prophylactic internal fixation prior to irradiation.

Entities:  

Mesh:

Year:  1989        PMID: 2684463

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  179 in total

Review 1.  Computed tomography-based rigidity analysis: a review of the approach in preclinical and clinical studies.

Authors:  Juan C Villa-Camacho; Otatade Iyoha-Bello; Shohreh Behrouzi; Brian D Snyder; Ara Nazarian
Journal:  Bonekey Rep       Date:  2014-11-05

2.  Lessons learnt from a case of multiple myeloma.

Authors:  Raju Vaishya; Amit Kumar Agarwal; Vipul Vijay
Journal:  BMJ Case Rep       Date:  2015-08-25

3.  Predicting Fracture Risk for Enchondroma of the Hand.

Authors:  Scott Riester; Rishi Ramaesch; Doris Wenger; Andre van Wijnen; Sanjeev Kakar
Journal:  Hand (N Y)       Date:  2016-02-02

4.  Percutaneous osteosynthesis in the pelvis in cancer patients.

Authors:  Frederic Deschamps; Thierry de Baere; Antoine Hakime; Ernesto Pearson; Geoffroy Farouil; Christophe Teriitehau; Lambros Tselikas
Journal:  Eur Radiol       Date:  2015-08-30       Impact factor: 5.315

5.  Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis.

Authors:  Ara Nazarian; Vahid Entezari; David Zurakowski; Nathan Calderon; John A Hipp; Juan C Villa-Camacho; Patrick P Lin; Felix H Cheung; Albert J Aboulafia; Robert Turcotte; Megan E Anderson; Mark C Gebhardt; Edward Y Cheng; Richard M Terek; Michael Yaszemski; Timothy A Damron; Brian D Snyder
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

6.  [Surgical treatment of skeletal metastases].

Authors:  T Gösling; M Becker-Schiebe
Journal:  Unfallchirurg       Date:  2015-04       Impact factor: 1.000

Review 7.  Metastatic bone cancer pain: etiology and treatment options.

Authors:  Gary C O'Toole; Patrick Boland
Journal:  Curr Pain Headache Rep       Date:  2006-08

8.  Surgical management of metastatic lesions of the proximal femur with pathological fractures using intramedullary nailing or endoprosthetic replacement.

Authors:  Zeping Yu; Yan Xiong; Rui Shi; Li Min; Wenli Zhang; Hongyuan Liu; Xiang Fang; Chongqi Tu; Hong Duan
Journal:  Mol Clin Oncol       Date:  2017-11-15

9.  [Surgical treatment of pathologic fractures of the humerus and femur].

Authors:  G Gruber; M Zacherl; A Leithner; C Giessauf; M Glehr; H Clar; R Windhager
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

10.  Inter- and intra-observer variability associated with the use of the Mirels' scoring system for metastatic bone lesions.

Authors:  Ruairi F Mac Niocaill; John F Quinlan; Robert D Stapleton; Brian Hurson; Sean Dudeney; Gary C O'Toole
Journal:  Int Orthop       Date:  2010-01-19       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.